Follow-up results of a randomized, double-blind, phase III, multi-center study to evaluate the safety and efficacy of BF-200 ALA versus placebo in field-directed treatment of mild to moderate AK with photodynamic therapy when using narrowband red light

Main Article Content

U Reinhold
T Dirschka
R Ostendorf
R Aschoff
C Berking
W Philipp-Dormston
R.M. Szeimies

Keywords

actinic keratosis, photodynamic therapy, BF-200 ALA, narrowband red light

Abstract

Abstract not available.

References

1. Reinhold, Uwe (2017): A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. In: Future oncology (London, England) 13(27): S. 2413-2428. DOI: 10.2217/fon-2017-0247.

2. Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED® lamp. Br J Dermatol. 2016; 175(4):696-705.